Nanoparticle-mediated efficient up-regulation of GSDMD-N to induce pyroptosis and enhance NK cell-based cancer immunotherapy
Source abstract
Abstract
Natural killer (NK) cell-based immunotherapy has emerged as a safe and effective therapeutic modality for cancer treatment. However, therapeutic benefits can be only seen in hematological tumors (e.g., leukemia) and the treatment of solid tumors is still less effective due to the immunosuppressive tumor microenvironment (TME)-induced poor infiltration and dysfunction of NK cells in tumor tissues. We herein developed a robust nucleus-targeted nanoparticle (NP) platform for systemic delivery of plasmid expressing the N-terminal domain of GSDMD (i.e., pGSDMD-N) and augment of NK cell-based immunotherapy for oral squamous cell carcinoma (OSCC). This nanoplatform is made of a PEGylated poly(2-(diisopropylamino) ethyl methacrylate) (PDPA) polymer and a nucleus-targeting peptide amphiphile (NTPA) that can complex pGSDMD-N. After intravenous administration, this nanoplatform could specifically deliver pGSDMD-N into the nuclei of OSCC cells, leading to their pyroptosis via up-regulating GSDMD-N expression. More importantly, this pyroptosis could boost NK cell-based immunotherapy via promoting the recruitment of NK cells into tumor tissues and enhancing their activation to further enhance the anticancer effect of the pGSDMD-N delivery system. STATEMENT OF SIGNIFICANCE: : NK cell-based immunotherapy has made a significant breakthrough in the treatment of hematological tumors (e.g., leukemia), but it is still less effective for solid tumors due to immunosuppressive tumor microenvironment (TME)-induced dysfunction of NK cells. We herein developed a nucleus-targeted nanoplatform for systemic delivery of plasmid expressing the N-terminal domain of gasdermin D (denoted pGSDMD-N) and augment of NK cell-based immunotherapy for oral squamous cell carcinoma (OSCC). This delivery system could not only induce the pyroptosis of OSCC cells, but also promote the secretion of functional chemokines (e.g., CCL3) and cytokines (e.g., IL-18) to boost NK cell-based immunotherapy. The strategy demonstrated herein could be a promising strategy to enhance the NK cell-based immunotherapy for solid tumors.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Immune Cell Function and Interaction · Toxoplasma gondii Research Studies · Inflammasome and immune disorders
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (52)
Show source-provided references
1. Innate lymphoid cells and cancer10.1038/s41590-022-01127-z ↗
2. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy10.1038/s41577-022-00732-1 ↗
3. D. Campana, NK cells for cancer immunotherapy10.1038/s41573-019-0052-1 ↗
4. Exploring the NK cell platform for cancer immunotherapy10.1038/s41571-020-0426-7 ↗
5. Negative signaling by inhibitory receptors: the NK cell paradigm10.1111/j.1600-065X.2008.00660.x ↗
6. Human NK cells: surface receptors, inhibitory checkpoints, and translational applications10.1038/s41423-019-0206-4 ↗
7. Natural killer cells in antitumour adoptive cell immunotherapy10.1038/s41568-022-00491-0 ↗
8. The NK cell-cancer cycle: advances and new challenges in NK cell–based immunotherapies10.1038/s41590-020-0728-z ↗
9. NK cell-based cancer immunotherapy: from basic biology to clinical development10.1186/s13045-020-01014-w ↗
10. Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors10.3389/fimmu.2019.03038 ↗
11. Improving cancer immunotherapy through nanotechnology10.1038/s41568-019-0186-9 ↗
12. Delivery technologies for cancer immunotherapy10.1038/s41573-018-0006-z ↗
13. Applications of nanotechnology for immunology10.1038/nri3488 ↗
14. Nanomaterial-boosted tumor immunotherapy through natural killer cells10.1002/anbr.202200096 ↗
15. Natural killer (NK) cell-based immunotherapies and the many faces of NK cell memory: a look into how nanoparticles enhance NK cell activity10.1016/j.addr.2021.113860 ↗
16. NK cell-based tumor immunotherapy10.1016/j.bioactmat.2023.08.001 ↗
17. Nanobiomaterials to modulate natural killer cell responses for effective cancer immunotherapy10.1016/j.tibtech.2022.06.011 ↗
18. Nanomaterials for natural killer cell-based immunoimaging and immunotherapies in cancer10.1021/acsami.2c08619 ↗
19. Selenium-containing nanoparticles synergistically enhance Pemetrexed&NK cell-based chemoimmunotherapy10.1016/j.biomaterials.2021.121321 ↗
20. Natural killer cell membrane infused biomimetic liposomes for targeted tumor therapy10.1016/j.biomaterials.2018.01.018 ↗
21. Cationic nanoparticle-mediated activation of natural killer cells for effective cancer immunotherapy10.1021/acsami.0c16357 ↗
22. Enhanced natural killer cell anti-tumor activity with nanoparticles mediated ferroptosis and potential therapeutic application in prostate cancer10.1186/s12951-022-01635-y ↗
23. Transforming growth factor-β signaling in immunity and cancer10.1016/j.immuni.2019.03.024 ↗
24. TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway10.1126/scisignal.aad1884 ↗
25. The role of cytokines in the regulation of NK cells in the tumor environment10.1016/j.cyto.2019.02.001 ↗
26. Emerging mechanisms of pyroptosis and its therapeutic strategy in cancer10.1038/s41420-022-01101-6 ↗
27. Pyroptosis: mechanisms and diseases, Signal Transduct
28. Nanomedicine-enabled/augmented cell pyroptosis for efficient tumor nanotherapy10.1002/advs.202203583 ↗
29. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death10.1038/nature15514 ↗
30. Pore-forming activity and structural autoinhibition of the gasdermin family10.1038/nature18590 ↗
31. Pyroptosis correlates with tumor immunity and prognosis10.1038/s42003-022-03806-x ↗
32. Enhancing Gasdermin-induced tumor pyroptosis through preventing ESCRT-dependent cell membrane repair augments antitumor immune response10.1038/s41467-022-34036-8 ↗
33. Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy10.1038/s41392-022-01046-3 ↗
34. Gasdermin E suppresses tumour growth by activating anti-tumour immunity10.1038/s41586-020-2071-9 ↗
35. mRNA lipid nanoparticle-mediated pyroptosis sensitizes immunologically cold tumors to checkpoint immunotherapy10.1038/s41467-023-39938-9 ↗
36. Efficient delivery of GSDMD-N mRNA by engineered extracellular vesicles induces pyroptosis for enhanced immunotherapy
37. Chemokine networks modulating natural killer cell trafficking to solid tumors10.1016/j.cytogfr.2020.12.003 ↗
38. Reduction-responsive RNAi nanoplatform to reprogram tumor lipid metabolism and repolarize macrophage for combination pancreatic cancer therapy10.1016/j.biomaterials.2021.121264 ↗
39. Nanoparticles (NPs)-mediated lncBCMA silencing to promote eEF1A1 ubiquitination and suppress breast cancer growth and metastasis10.1016/j.apsb.2022.12.004 ↗
40. Remodeling of mitochondrial metabolism by a mitochondria-targeted RNAi Nanoplatform for effective cancer therapy10.1002/smll.202305923 ↗
41. Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment10.1073/pnas.1505629112 ↗
42. Single-step assembly of homogenous lipid-polymeric and lipid-quantum dot nanoparticles enabled by microfluidic rapid mixing10.1021/nn901433u ↗
43. Pyroptosis: gasdermin-mediated programmed necrotic cell death10.1016/j.tibs.2016.10.004 ↗
44. Tunable, Ultrasensitive pH-responsive nanoparticles targeting specific endocytic organelles in living cells10.1002/anie.201100884 ↗
45. Role of long non-coding RNAs in cancer: from subcellular localization to nanoparticle-mediated targeted regulation10.1016/j.omtn.2023.07.009 ↗
46. Nucleus-specific RNAi nanoplatform for targeted regulation of nuclear lncRNA function and effective cancer therapy
47. Targeted delivery to the nucleus10.1016/j.addr.2007.06.010 ↗
48. Importin α: a multipurpose nuclear-transport receptor10.1016/j.tcb.2004.07.016 ↗
49. Remodeling serine synthesis and metabolism via nanoparticles (NPs)-mediated CFL1 silencing to enhance the sensitivity of hepatocellular carcinoma to sorafenib10.1002/advs.202207118 ↗
50. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives10.1002/anie.200902672 ↗
51. Natural killer cell depletion by anti-asialo GM1 antiserum treatment enhances human hematopoietic stem cell engraftment in NOD/Shi-SCID mice10.1038/sj.bmt.1702702 ↗
52. Humanized mice for the study of immuno-oncology10.1016/j.it.2018.07.001 ↗